Clinical Pharmacokinetics of Daprodustat: Results of an Absorption, Distribution, and Excretion Study With Intravenous Microtracer and Concomitant Oral Doses for Bioavailability Determination
Authors:
Open Access
- 28 October 2021
- journal article
- research article
- Published by Wiley in Clinical Pharmacology in Drug Development
- Vol. 10 (12) , 1419-1431
Abstract
Daprodustat, an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor, is being investigated for treatment of anemia in chronic kidney disease. This phase 1, nonrandomized, 2‐period, crossover study in 6 healthy men characterized the absorption, distribution, and excretion of daprodustat when administered as oral and intravenous (IV) doses of unlabeled and radiolabeled daprodustat ([14C]‐GSK1278863). Tolerability and pharmacokinetic properties of daprodustat, and its 6 metabolites in the systemic circulation, were also evaluated. The mean recovery of radiolabeled daprodustat was ≈95% by day 5, with the majority in feces and minor renal elimination, indicating that daprodustat and metabolites are primarily eliminated via hepatobiliary and fecal routes. Approximately 40% of total circulating radioactivity in plasma following both IV and oral administration was daprodustat; thus, 60% was attributed to metabolites. It was estimated that ≈80% of daprodustat was absorbed across the gastrointestinal tract, and ≈18% cleared by hepatic extraction. Pharmacokinetics were essentially dose proportional, with moderate (≈66%) oral tablet bioavailability. Following IV administration, daprodustat plasma clearance (19.3 L/h) and volume of distribution (14.6 L) were low, suggesting low tissue distribution outside systemic circulation with likely low penetration into tissues. Daprodustat was generally well tolerated, with no deaths or serious or significant adverse events reported.Keywords
Funding Information
- GlaxoSmithKline
This publication has 24 references indexed in Scilit:
- Investigational therapies for renal disease-induced anemiaExpert Opinion on Investigational Drugs, 2016
- Overcoming bioanalytical challenges associated with the separation and quantitation of GSK1278863, a HIF-prolyl hydroxylase inhibitor, and its 14 stereoisomeric metabolitesJournal of Chromatography B, 2016
- Approaches to intravenous clinical pharmacokinetics: Recent developments with isotopic microtracersThe Journal of Clinical Pharmacology, 2015
- Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery diseaseVascular Medicine, 2014
- Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863Clinical Pharmacology in Drug Development, 2013
- Concomitant Oral and Intravenous Pharmacokinetics of Dabrafenib, a BRAF Inhibitor, in Patients with BRAF V600 Mutation‐Positive Solid TumorsThe Journal of Clinical Pharmacology, 2013
- Simultaneous oral therapeutic and intravenous 14C‐microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozinBritish Journal of Clinical Pharmacology, 2013
- Use of Entero‐Test, a simple approach for non‐invasive clinical evaluation of the biliary disposition of drugsBritish Journal of Clinical Pharmacology, 2011
- Human radiolabeled mass balance studies: objectives, utilities and limitationsBiopharmaceutics & Drug Disposition, 2009
- Differential expression and function of CYP2C isoforms in human intestine and liverPharmacogenetics, 2003